{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:12:35Z","timestamp":1778811155654,"version":"3.51.4"},"reference-count":33,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["grant 058299\/Z\/99"],"award-info":[{"award-number":["grant 058299\/Z\/99"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To investigate the trends in diabetes prevalence, diagnosis, and management among Mexican adults who were participants in a long-term prospective study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>From 1998 to 2004, 159,755 adults from Mexico City were recruited to a prospective study, and from 2015 to 2019, 10,144 survivors were resurveyed. Diabetes was defined as self-reported diagnosis, glucose-lowering medication use, or HbA1c \u22656.5%. Controlled diabetes was defined as HbA1c &amp;lt;7%. Prevalence estimates were uniformly standardized for age, sex, and residential district. Cox models explored the relevance of controlled and inadequately controlled diabetes to cause-specific mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>During 1998\u20132004 and 2015\u20132019, 99,623 and 8,986 participants were aged 45\u201384 years. Diabetes prevalence had increased from 26% in 1998\u20132004 to 35% by 2015\u20132019. Of those with diabetes, the proportion previously diagnosed had increased from 76% to 89%, and glucose-lowering medication use among them had increased from 80% to 94%. Median HbA1c among those with diabetes had decreased from 8.2% to 7.3%, and the proportion of participants with controlled diabetes had increased from 16% to 37%. Use of blood pressure\u2013lowering medication among those with previously diagnosed diabetes had increased from 35% to 51%, and their use of lipid-lowering therapy had increased from 1% to 14%. The excess mortality risk associated with diabetes accounted for 34% of deaths at ages 35\u201374 years, of which 5% were attributable to controlled and 29% to inadequately controlled diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Inadequately controlled diabetes is a leading cause of premature adult death in Mexico. Improvements in diabetes management have increased diagnosis and control, but substantial opportunities remain to improve treatment, particularly with lipid-lowering therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc20-2276","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T23:25:26Z","timestamp":1612999526000},"page":"944-951","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":22,"title":["Changes in the Diagnosis and Management of Diabetes in Mexico City Between 1998\u20132004 and 2015\u20132019"],"prefix":"10.2337","volume":"44","author":[{"given":"Diego","family":"Aguilar-Ramirez","sequence":"first","affiliation":[{"name":"Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Alegre-D\u00edaz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Gnatiuc","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Ramirez-Reyes","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Wade","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."},{"name":"MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hill","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."},{"name":"MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory","family":"Collins","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Peto","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-9422","authenticated-orcid":false,"given":"Jonathan R.","family":"Emberson","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."},{"name":"MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Herrington","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."},{"name":"MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Kuri-Morales","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Tapia-Conyer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"2022031309472250900_B1","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa1605368","article-title":"Diabetes and cause-specific mortality in Mexico City","volume":"375","author":"Alegre-D\u00edaz","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031309472250900_B2","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 9th edition\n          , 2019. Accessed 28 May 2020. Available from https:\/\/diabetesatlas.org\/en\/resources\/"},{"key":"2022031309472250900_B3","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(09)60239-7","article-title":"Public policy for the poor? A randomised assessment of the Mexican universal health insurance programme","volume":"373","author":"King","year":"2009","journal-title":"Lancet"},{"key":"2022031309472250900_B4","unstructured":"Bonilla-Chac\u00edn\u2008ME, Aguilera\u2008N. The Mexican social protection system in health (English). Universal Health Coverage (UNICO) studies series; no. 1, 2013. Accessed 1 July 2020. Available from https:\/\/documents.worldbank.org\/curated\/en\/960791468045021860\/The-Mexican-social-protection-system-in-health"},{"key":"2022031309472250900_B5","article-title":"Estrategia nacional para la prevenci\u00f3n y el control del sobrepeso, la obesidad y la diabetes","author":"Gobierno de la Rep\u00fablica","year":"2013"},{"key":"2022031309472250900_B6","unstructured":"Secretar\u00eda\u2008de Salud\n          . Emite la Secretar\u00eda de Salud emergencia epidemiol\u00f3gica por diabetes mellitus y obesidad. Accessed 6 May 2020. Available from https:\/\/www.gob.mx\/salud\/prensa\/emite-la-secretaria-de-salud-emergencia-epidemiologica-por-diabetes-mellitus-y-obesidad"},{"key":"2022031309472250900_B7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031309472250900_B8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-8587(18)30050-0","article-title":"Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study","volume":"6","author":"Herrington","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031309472250900_B9","unstructured":"Olaiz\u2008G, Rojas\u2008R, Barquera\u2008S, et al. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos, 2003. Accessed 19 May 2020. Available from https:\/\/ensanut.insp.mx\/encuestas\/ensa2000\/informes.php"},{"key":"2022031309472250900_B10","unstructured":"Olaiz-Fern\u00e1ndez\u2008G, Rivera-Dommarco\u2008J, Shamah-Levy\u2008T, Rojas\u2008R, Villalpando-Hern\u00e1ndez\u2008S, Hern\u00e1ndez-Avila\u2008M, Sep\u00falveda-Amor\u2008J. Encuesta Nacional de Salud y Nutrici\u00f3n 2006. Accessed 19 May 2020. Available from https:\/\/ensanut.insp.mx\/encuestas\/ensanut2006\/informes.php"},{"key":"2022031309472250900_B11","unstructured":"Guti\u00e9rrez\u2008JP, Rivera-Dommarco\u2008J, Shamah-Levy\u2008T, et al. Encuesta Nacional de Salud y Nutrici\u00f3n 2012. Resultados Nacionales, 2012. Accessed 19 May 2020. Available from https:\/\/ensanut.insp.mx\/encuestas\/ensanut2012\/informes.php"},{"key":"2022031309472250900_B12","unstructured":"Hern\u00e1ndez \u00c1vila\u2008M, Rivera-Dommarco\u2008J, Shamah-Levy\u2008T. Encuesta Nacional de Salud y Nutrici\u00f3n - MC 2016. Accessed 19 May 2020. Available from https:\/\/ensanut.insp.mx\/encuestas\/ensanut2016\/informes.php"},{"key":"2022031309472250900_B13","first-page":"50","article-title":"Prevalence of diabetes and poor glycemic control in Mexico: results from Ensanut 2016","volume-title":"Salud Publica Mex","author":"Basto-Abreu","year":"2019"},{"key":"2022031309472250900_B14","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1590\/S0036-36342010000700005","article-title":"Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey","volume":"52","author":"Villalpando","year":"2010","journal-title":"Salud Publica Mex"},{"key":"2022031309472250900_B15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/clinchem\/48.9.1627","article-title":"Reliable measurement of glycated hemoglobin in frozen blood samples: implications for epidemiologic studies","volume":"48","author":"Youngman","year":"2002","journal-title":"Clin Chem"},{"key":"2022031309472250900_B16","unstructured":"International Federation of Clinical Chemistry\n          . Standardization of HbA1c. NGSP. Accessed 6 May 2020. Available from http:\/\/www.ngsp.org\/docs\/IFCCstd.pdf"},{"key":"2022031309472250900_B17","volume-title":"Global Guideline for Type 2 Diabetes","author":"International Diabetes Federation Clinical Guidelines Task Force","year":"2005"},{"key":"2022031309472250900_B18","unstructured":"Global Burden of Disease Collaborative Network\n          . Global burden of disease study 2017 (GBD 2017) results, 2018. Accessed 28 May 2020. Available from https:\/\/ghdx.healthdata.org\/gbd-results-tool"},{"key":"2022031309472250900_B19","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s11606-019-05587-2","article-title":"Trends in diabetes management among US adults: 1999-2016","volume":"35","author":"Fang","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2022031309472250900_B20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ypmed.2015.10.015","article-title":"Burden of type 2 diabetes in Mexico: past, current and future prevalence and incidence rates","volume":"81","author":"Meza","year":"2015","journal-title":"Prev Med"},{"key":"2022031309472250900_B21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21149\/spm.v56i1.7318","article-title":"Incidence of type 2 diabetes in Mexico: results of the Mexico City Diabetes Study after 18 years of follow-up","volume":"56","author":"Gonz\u00e1lez-Villalpando","year":"2014","journal-title":"Salud Publica Mex"},{"key":"2022031309472250900_B22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"2022031309472250900_B23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2022031309472250900_B24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031309472250900_B25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022031309472250900_B26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/nutrit\/nuw030","article-title":"Epidemiology of diabetes mellitus in Mexico","volume":"75","author":"Bello-Chavolla","year":"2017","journal-title":"Nutr Rev"},{"key":"2022031309472250900_B27","first-page":"7","article-title":"Diagn\u00f3stico y tratamiento de las dislipidemias: posici\u00f3n de la Sociedad Mexicana de Nutrici\u00f3n y Endocrinolog\u00eda","volume":"12","author":"Aguilar","year":"2004","journal-title":"Rev Endocrinol Nutr"},{"key":"2022031309472250900_B28","unstructured":"Prevenci\u00f3n, diagn\u00f3stico, tratamiento inicial, metas de control ambulatorio y referencia oportuna de la diabetes mellitus tipo 2 en el primer nivel de atenci\u00f3n. Gu\u00eda de Evidencias y Recomendaciones. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica, 2019. Accessed 13 August 2020. Available from https:\/\/www.cenetec-difusion.com\/CMGPC\/GPC-SS-093-19\/ER.pdf"},{"key":"2022031309472250900_B29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2022031309472250900_B30","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"2022031309472250900_B31","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess mortality among persons with type 2 diabetes","volume":"373","author":"Tancredi","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031309472250900_B32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"2022031309472250900_B33","unstructured":"World Health Organization\n          . Global action plan for the prevention and control of noncommunicable diseases 2013-2020, 2013. Accessed 1 July 2020. Available from https:\/\/apps.who.int\/iris\/handle\/10665\/94384"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc20-2276","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/4\/944\/632138\/dc202276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/4\/944\/632138\/dc202276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T10:53:25Z","timestamp":1647168805000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/44\/4\/944\/138608\/Changes-in-the-Diagnosis-and-Management-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,10]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-2276","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]}}}